NASDAQ:URGN - Urogen Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Urogen Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.00 +0.50 (+3.03 %) (As of 04/2/2020 04:00 PM ET) Add Compare Today's Range$16.34Now: $17.00▼$17.9850-Day Range$13.68MA: $23.81▼$30.2852-Week Range$13.12Now: $17.00▼$41.21Volume241,600 shsAverage Volume186,980 shsMarket Capitalization$355.25 millionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins. The company was incorporated in 2004 and is based in New York, New York.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:URGN Previous Symbol CUSIPN/A CIK1668243 Webhttp://www.urogen.com/ Phone646-768-9780Debt Debt-to-Equity RatioN/A Current Ratio7.63 Quick Ratio7.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales17,762.45 Cash FlowN/A Price / Cash FlowN/A Book Value$8.63 per share Price / Book1.97Profitability EPS (Most Recent Fiscal Year)($5.12) Net Income$-105,150,000.00 Net MarginsN/A Return on Equity-49.16% Return on Assets-45.73%Miscellaneous Employees70 Outstanding Shares20,897,000Market Cap$355.25 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive URGN News and Ratings via Email Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:URGN Rates by TradingView Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions How has Urogen Pharma's stock been impacted by COVID-19 (Coronavirus)? Urogen Pharma's stock was trading at $23.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, URGN stock has decreased by 28.8% and is now trading at $17.00. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Urogen Pharma? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Urogen Pharma. When is Urogen Pharma's next earnings date? Urogen Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Urogen Pharma. How were Urogen Pharma's earnings last quarter? Urogen Pharma Ltd (NASDAQ:URGN) announced its earnings results on Monday, March, 2nd. The company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.70) by $0.16. View Urogen Pharma's earnings history. What price target have analysts set for URGN? 7 Wall Street analysts have issued twelve-month target prices for Urogen Pharma's shares. Their forecasts range from $37.00 to $75.00. On average, they expect Urogen Pharma's share price to reach $48.83 in the next twelve months. This suggests a possible upside of 187.3% from the stock's current price. View analysts' price targets for Urogen Pharma. What are Wall Street analysts saying about Urogen Pharma stock? Here are some recent quotes from research analysts about Urogen Pharma stock: 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (3/4/2020) 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating after URGN’s investor day as we came away more bullish on UGN-101 as a treatment for LG-UTUC based on commentary from the physician panel which we believe did a good job addressing many of the investor concerns we hear. Additionally, URGN also reported encouraging results for UGN-102 in LG-NMIBC. While we concede LG-UTUC is a small market, we think investors are meaningfully discounting UGN-101’s commercial potential in the face of the clear unmet need for a non-surgical, kidney sparing treatment which was highlighted by the panel. UGN-101 has a high probability of approval, in our view, though we think shares could be range bound until approval/ launch, likely in 1H20." (9/24/2019) Has Urogen Pharma been receiving favorable news coverage? Media headlines about URGN stock have been trending very negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Urogen Pharma earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutUrogen Pharma. Are investors shorting Urogen Pharma? Urogen Pharma saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 2,126,500 shares, a decline of 11.8% from the February 27th total of 2,410,000 shares. Based on an average trading volume of 220,300 shares, the days-to-cover ratio is currently 9.7 days. Currently, 13.4% of the shares of the company are sold short. View Urogen Pharma's Current Options Chain. Who are some of Urogen Pharma's key competitors? Some companies that are related to Urogen Pharma include BELLUS Health (BLUSF), Turning Point Therapeutics (TPTX), Amarin (AMRN), Epizyme (EPZM), Pacira Biosciences (PCRX), SAGE Therapeutics (SAGE), Akcea Therapeutics (AKCA), Theravance Biopharma (TBPH), Corcept Therapeutics (CORT), Insmed (INSM), Karyopharm Therapeutics (KPTI), CytoDyn (CYDY), Constellation Pharmaceuticals (CNST), Dicerna Pharmaceuticals (DRNA) and Innoviva (INVA). What other stocks do shareholders of Urogen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Urogen Pharma investors own include Kite Pharma (KITE), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Exelixis (EXEL), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Nektar Therapeutics (NKTR), NVIDIA (NVDA), Sangamo Therapeutics (SGMO) and Aduro BioTech (ADRO). Who are Urogen Pharma's key executives? Urogen Pharma's management team includes the following people: Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)Mr. Stephen Mullennix, Chief Operating OfficerMs. Catherine Bechtold, Director of Corp. Communications & Investor RelationsDr. Sari Prutchi-Sagiv Ph.D., Marketing Director When did Urogen Pharma IPO? (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. What is Urogen Pharma's stock symbol? Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN." How do I buy shares of Urogen Pharma? Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Urogen Pharma's stock price today? One share of URGN stock can currently be purchased for approximately $17.00. How big of a company is Urogen Pharma? Urogen Pharma has a market capitalization of $355.25 million and generates $20,000.00 in revenue each year. The company earns $-105,150,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe. View additional information about Urogen Pharma. What is Urogen Pharma's official website? The official website for Urogen Pharma is http://www.urogen.com/. How can I contact Urogen Pharma? Urogen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at 646-768-9780 or via email at [email protected] MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 322 (Vote Outperform)Underperform Votes: 208 (Vote Underperform)Total Votes: 530MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/2/2020 by MarketBeat.com StaffFeatured Article: Why does the United States have a lingering trade deficit?
